Shares of AngioDynamics (ANGO) Sees Large Outflow of Money

AngioDynamics (ANGO) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (1.73 million) in AngioDynamics (ANGO). On Wednesday, The value of composite uptick trades was $0.21 million, whereas, the value of composite downtick trades was $1.93 million and the ratio between the two was 0.11, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $1.65 million. The negative money flow of ($1.65 million) shows selling on strength. AngioDynamics (ANGO) gained $0.1 intraday at $16.82 and registrered 0.57% for the week.


Also, Piper Jaffray assumes their rating on the shares of AngioDynamics (NASDAQ:ANGO). The current rating of the shares is Neutral. The rating by the firm was issued on April 8, 2016.

AngioDynamics (NASDAQ:ANGO): The stock opened at $16.70 on Wednesday but the bulls could not build on the opening and the stock topped out at $16.99 for the day. The stock traded down to $16.11 during the day, due to lack of any buying support eventually closed down at $16.70 with a loss of -0.12% for the day. The stock had closed at $16.72 on the previous day. The total traded volume was 273,192 shares.

The stock has recorded a 20-day Moving Average of 14.38% and the 50-Day Moving Average is 24.88%. In a related news,The officer (VP – Global Franchise) of Angiodynamics Inc, Greiner Charles R sold 3,508 shares at $12.31 on May 6, 2016. The Insider selling transaction had a total value worth of $43,183. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Companys devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Companys Peripheral Vascular products include fluid management, venous, thrombus management, as well as other core products. The Companys BioFlo products incorporate Endexo technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its microwave ablation products, its radiofrequency ablation (RFA) and its NanoKnife product lines.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.